A securities class action has been filed against Vistagen Therapeutics, Inc. (VTGN) on behalf of persons and entities that purchased or otherwise acquired Vistagen securities between January 25, 2024 through March 4, 2025. This case has been filed in the USDC – NDCA.
On December 17, 2025, before the market opened, Vistagen announced topline results from its PALISADE-3 Public Speaking Challenge Study of fasedienol for the acute treatment of social anxiety disorder (SAD).
The company reported that the study failed to meet its primary efficacy endpoint since it “did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placebo.”
Following this news, VTGN’s stock price fell over 81% to open at $0.88 per share.